Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.48 |
| ▸ | CDK2 | P24941 | 6/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.45 |
| ▸ | PAK4 | O96013 | 2/20 | 0.45 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.45 |
| ▸ | IGF1R | P08069 | 7/20 | 0.44 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1710850 | 0.80 | JAK2 (0.49) | JAK2 | |
| SCHEMBL1268963 | 0.80 | IGF1R (0.56) | CDK2IGF1RCCNE2CCNE1 | |
| SCHEMBL1270104 | 0.80 | IGF1R (0.56) | CDK2IGF1RCCNE2CCNE1 | |
| SCHEMBL13430135 | 0.79 | JAK2 (0.77) | JAK2CDK2IGF1RCCNE2CCNE1 | |
| SCHEMBL1269162 | 0.78 | IGF1R (0.69) | CDK2IGF1RCCNE2CCNE1 | |
| SCHEMBL1269907 | 0.78 | IGF1R (0.69) | CDK2IGF1RCCNE2CCNE1 | |
| SCHEMBL1269884 | 0.78 | IGF1R (0.53) | CDK2CCNA2CCNA1IGF1RCCNE2 | |
| SCHEMBL1269525 | 0.78 | IGF1R (0.53) | CDK2CCNA2CCNA1IGF1RCCNE2 | |
| SCHEMBL1268925 | 0.78 | IGF1R (0.45) | CDK2CCNA2CCNA1IGF1RCCNE2 | |
| SCHEMBL1269100 | 0.78 | IGF1R (0.66) | CDK2IGF1RCCNE2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344504-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-04 | — | — | EP | disclosed |
| US-8445676-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110294816-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294816-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | JAK2, CSNK2A1, CSNK2A2 | JAK2 1/4885CDK2 5/4885CCNA2 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.